$MRNA just proved AI is not a Bubble 💰 Moderna has used artificial intelligence and machine learning extensively to accelerate research and development of its personalized mRNA cancer vaccine (individualized neoantigen therapy/INT, also known as mRNA-4157/V940 or intismeran autogene, developed with Merck). This is a landmark validation that AI can deliver massive practical ROI in a high value therapeutic area (personalized cancer vaccines), not merely theoretical or preclinical gains. But it builds on a growing body of earlier AI successes in speed, cost, and early clinical progress rather than being the absolute first. As more late stage and approved AI-influenced drugs emerge, the ROI case will strengthen further across the industry. Neoantigen selection and design: Tumor and blood s
View on X ↗